权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional Analysis of O-GlcNAc using Synthetic Protein Chemistry

使用合成蛋白质化学对 O-GlcNAc 进行功能分析

基本信息

批准号：
10460615
负责人：
Matthew Robert Pratt
金额：
$ 34.69万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10460615
关键词：
Acetylation Affect Amyloid Animals Biochemical Biochemistry Biological Biology Biophysics Carbohydrates Cellular biology Charcot-Marie-Tooth Disease Chemicals Collaborations Cryoelectron Microscopy Data Development Diabetes Mellitus Diffusion Disease Embryonic Development Excision Functional disorder Funding Goals Grant HSPB1 gene Heat shock proteins Kinetics Knowledge Ligation Malignant Neoplasms Mammals Measures Methods Michigan Modification Molecular Molecular Chaperones Monosaccharides Mus Mutagenesis Mutation Nerve Degeneration Neurodegenerative Disorders Neurons Neuropathy O-GlcNAc transferase Parkinson Disease Pathogenicity Pathway interactions Patients Peripheral Nervous System Diseases Phosphorylation Play Point Mutation Polymorph Post-Translational Protein Processing Protein Chemistry Proteins Proteomics Publishing Recombinant Proteins Research Role Serine Serine/Threonine Phosphorylation Silicon Dioxide Site Structure Testing Therapeutic Threonine Time Toxic effect Western Blotting Work alpha synuclein amyloid formation amyloid structure base biophysical properties dark matter experimental study glycosylation human disease in vivo monomer mutant prevent programs protein aggregation protein function public health relevance stereochemistry sugar synthetic protein unnatural amino acids

项目摘要

Modified Project Summary/Abstract (The abstract contained no specific references to the in vivo mouse experiments and therefore is unchanged): O-GlcNAc modification is a dynamic protein-modification that is absolutely required for embryonic development in mammals, and is misregulated in diseases, including diabetes, neurodegeneration and cancer. Although approximately 1,000 proteins are modified by O-GlcNAc, the effects of the vast majority of these modifications on protein function are completely unknown. The long-term goal of our research program is to fill in these missing gaps by determining the biochemical consequences of O-GlcNAc on proteins that are key to human disease. To accomplish this goal, we use a combination of carbohydrate and synthetic protein chemistries to build O-GlcNAc modified proteins for subsequent biological experiments. This chemical approach is uniquely enabling, as it is currently the only way to generate homogeneous and site-specifically O-GlcNAc modified proteins. We have been very successful and have used synthetic proteins to determine that O-GlcNAc has a multifaceted role in preventing the amyloid aggregation of proteins in neurodegenerative diseases. Specifically, we have found that O-GlcNAc both directly inhibits the aggregation of amyloid forming proteins and activates the activity of certain small chaperones. In this proposal we will continue to build on these discoveries. In Aim 1, we will determine how O-GlcNAc inhibits the early stages of α-synuclein amyloid formation. In Aim 2, we will test whether O-GlcNAc alters the structure/toxicity relationships of α-synuclein amyloids. In Aim 3, we examine how O-GlcNAc alters the small heat shock protein interactome. Finally, in Aim 4, we will determine if O-GlcNAc can rescue the activity of mutant chaperones that cause Charcot-Marie-Tooth disease. At the conclusion of these independent aims, we will have further unravelled the mechanisms by which O-GlcNAc inhibits protein aggregation and provided critical data to support the ongoing efforts to target O-GlcNAc therapeutically.

修改后的项目摘要/摘要（摘要未包含体内小鼠实验的具体参考文献，因此未发生变化）：O-GlcNAc修饰是哺乳动物胚胎发育绝对需要的动态蛋白质修饰，并且在疾病（包括糖尿病、神经变性和癌症）中失调。虽然大约有1,000种蛋白质被O-GlcNAc修饰，但这些修饰中的绝大多数对蛋白质功能的影响完全未知。我们研究计划的长期目标是通过确定O-GlcNAc对人类疾病关键蛋白质的生化后果来填补这些缺失的空白。为了实现这一目标，我们使用碳水化合物和合成蛋白质化学的组合来构建O-GlcNAc修饰的蛋白质用于随后的生物实验。这种化学方法是独特的，因为它是目前唯一的方法来产生同质和位点特异性O-GlcNAc修饰的蛋白质。我们已经非常成功地使用合成蛋白质来确定O-GlcNAc在预防神经退行性疾病中蛋白质的淀粉样蛋白聚集方面具有多方面的作用。具体地，我们已经发现O-GlcNAc既直接抑制淀粉样蛋白形成蛋白的聚集，又激活某些小分子伴侣蛋白的活性。在本提案中，我们将继续以这些发现为基础。在目标1中，我们将确定O-GlcNAc如何抑制α-突触核蛋白淀粉样蛋白形成的早期阶段。在目的2中，我们将测试O-GlcNAc是否改变α-突触核蛋白淀粉样蛋白的结构/毒性关系。在目标3中，我们研究了O-GlcNAc如何改变小的热休克蛋白相互作用组。最后，在目标4中，我们将确定O-GlcNAc是否可以拯救引起腓骨肌萎缩症的突变分子伴侣的活性。在这些独立目标的结论中，我们将进一步揭示O-GlcNAc抑制蛋白质聚集的机制，并提供关键数据来支持正在进行的治疗靶向O-GlcNAc的努力。